Skip to content
10-Q

Quarterly Report

Solid Biosciences Inc. SLDB

0000950170-24-060034

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 38.38M sh
Current Liabilities Q1 2024 · Mar 31, 2024 $14.34M
Current Liabilities Q1 2024 · Dec 31, 2023 $14.52M
Total Liabilities Q1 2024 · Mar 31, 2024 $37.97M
Total Liabilities Q1 2024 · Dec 31, 2023 $38.46M
Current Assets Q1 2024 · Mar 31, 2024 $214.19M
Current Assets Q1 2024 · Dec 31, 2023 $129.73M
Total Assets Q1 2024 · Mar 31, 2024 $248.69M
Total Assets Q1 2024 · Dec 31, 2023 $164.94M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $74.02M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $164.65M
Shares Diluted Q1 2024 · Mar 31, 2023 19.57M sh
Capex Q1 2024 · Mar 31, 2023 $506K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$28M
Stockholders Equity Q1 2024 · Mar 31, 2023 $183.79M
Stockholders Equity Q1 2024 · Dec 31, 2022 $211.67M
Eps Diluted Q1 2024 · Mar 31, 2023 −$1.54
Eps Basic Q1 2024 · Mar 31, 2023 −$1.54
Sga Expense Q1 2024 · Mar 31, 2023 $7.4M
Rd Expense Q1 2024 · Mar 31, 2023 $24.63M
Operating Income Q1 2024 · Mar 31, 2023 −$32.03M